Dr. Severance is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
960 E Vermont Dr
Suite 208
Gilbert, AZ 85295Phone+1 480-329-6857Fax+1 480-775-1118
Summary
- Randall Severance, MD, is an internal medicine specialist based in Gilbert, AZ. He completed his medical education at Saint Louis University School of Medicine in 1987 and his residency in internal medicine at the University of Arizona College of Medicine-Phoenix, concluding in 1991. Dr. Severance has contributed to research with a publication on the efficacy and safety of alirocumab, cited 160 times, in the journal Atherosclerosis. He has been involved in several clinical trials focusing on diabetes management and dyslipidemia treatments, including studies on dulaglutide and combination therapies for dyslipidemia.
Education & Training
University of Arizona College of Medicine-PhoenixResidency, Internal Medicine, 1987 - 1991
Saint Louis University School of MedicineClass of 1987
Certifications & Licensure
AZ State Medical License 1991 - 2026
Clinical Trials
- Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia Start of enrollment: 2007 Jul 01
- 12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia Start of enrollment: 2007 Oct 01
- Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM Start of enrollment: 2015 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 11 citationsSafety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ...Randall Severance, Howard I Schwartz, Ron Dagan, Laurie Connor, Jianing Li
Human Vaccines & Immunotherapeutics. 2021-11-02 - 159 citationsEfficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OP...Michel Farnier, Peter B. Jones, Randall Severance, Maurizio Averna, Elisabeth Steinhagen-Thiessen
Atherosclerosis. 2016-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
